Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19043567 | HUMANIZED ANTI-TISSUE FACTOR ANTIBODY, ANTIBODY-DRUG CONJUGATE PREPARED THEREFROM AND USE THEREOF | February 2025 | June 2025 | Allow | 4 | 0 | 0 | Yes | No |
| 18910550 | ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | October 2024 | March 2025 | Allow | 6 | 1 | 0 | No | No |
| 18664078 | BINDING AGENTS TARGETING TROP2-EXPRESSING TUMOR CELLS | May 2024 | April 2025 | Allow | 11 | 2 | 0 | Yes | No |
| 18612088 | ANTI-CUB DOMAIN-CONTAINING PROTEIN 1 (CDCP1) ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND METHODS OF USE THEREOF | March 2024 | September 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18612866 | ANTI-CUB DOMAIN-CONTAINING PROTEIN 1 (CDCP1) ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND METHODS OF USE THEREOF | March 2024 | September 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18440860 | ANTI-CD28 X ANTI-PSMA ANTIBODIES | February 2024 | April 2025 | Allow | 14 | 2 | 1 | No | No |
| 18543673 | CD28/OX40 BISPECIFIC ANTIBODIES | December 2023 | May 2024 | Allow | 5 | 0 | 1 | Yes | No |
| 18510256 | Anti-cMet Antibody-Drug Conjugates and Uses Thereof | November 2023 | May 2025 | Allow | 18 | 4 | 1 | Yes | No |
| 18346130 | CHIMERIC ANTIGEN RECEPTOR FOR TUMOR TARGETING | June 2023 | June 2024 | Allow | 11 | 1 | 0 | No | No |
| 18149593 | BISPECIFIC SARS-COV-2 ANTIBODIES AND METHODS OF USE | January 2023 | September 2024 | Allow | 21 | 2 | 1 | No | No |
| 18082695 | IL-23 Specific Antibodies for the Treatment of Systemic Sclerosis | December 2022 | May 2025 | Abandon | 29 | 2 | 0 | No | Yes |
| 18062453 | PROTEINS BINDING NKG2D, CD16 AND 5T4 | December 2022 | April 2024 | Abandon | 17 | 0 | 1 | No | No |
| 17986374 | Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody | November 2022 | December 2024 | Abandon | 25 | 2 | 0 | No | Yes |
| 18053955 | ANTIBODY MOLECULES AND CONJUGATES | November 2022 | April 2024 | Allow | 17 | 1 | 1 | No | No |
| 18052174 | METHODS OF TREATING CANCERS AND ENHANCING EFFICACY OF BCMAXCD3 BISPECIFIC ANTIBODIES | November 2022 | May 2024 | Allow | 18 | 1 | 0 | No | No |
| 17937850 | METHOD FOR TREATING PD-L1 EXPRESSING CANCER | October 2022 | April 2025 | Abandon | 30 | 3 | 1 | No | No |
| 17932039 | HUMAN MONOCARBOXYLATE TRANSPORTER 1 ANTIBODIES AND USES THEREOF | September 2022 | January 2024 | Allow | 16 | 0 | 1 | Yes | No |
| 17929518 | METHODS OF TREATING CANCER AND TUMOR-RELATED WEIGHT LOSS AND CACHEXIA | September 2022 | October 2024 | Abandon | 25 | 0 | 1 | No | No |
| 17825511 | GENERATION OF A NEW SITE-SPECIFIC MONOCLONAL ANTIBODY FOR TAU PROTEIN AND ITS USE AS A TOOL IN SPECIFIC BIOMARKERS FOR EARLY DETECTION OF NEURODEGENERATIVE DISEASES AND PATHOLOGIES | May 2022 | January 2025 | Allow | 32 | 2 | 0 | Yes | No |
| 17712787 | METHOD FOR PREPARING T CELLS FOR ADOPTIVE T CELL THERAPY | April 2022 | October 2024 | Abandon | 30 | 1 | 1 | No | No |
| 17592012 | Antibodies for Botulinum Neurotoxins | February 2022 | June 2025 | Allow | 40 | 0 | 0 | Yes | No |
| 17555636 | ASSAYS FOR DETERMINING PLASMA KALLIKREIN SYSTEM BIOMARKERS | December 2021 | June 2025 | Allow | 42 | 3 | 0 | No | No |
| 17541837 | Antibodies for Botulinum Neurotoxins | December 2021 | July 2025 | Allow | 43 | 1 | 0 | No | No |
| 17497069 | Immunomodulatory Peptides | October 2021 | January 2024 | Allow | 27 | 1 | 1 | Yes | No |
| 17601354 | BISPECIFIC ANTIBODY | October 2021 | February 2025 | Allow | 40 | 1 | 0 | No | No |
| 17427780 | TCR FUSION PROTEIN AND CELL EXPRESSING TCR FUSION PROTEIN | August 2021 | May 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17425564 | MONOCLONAL ANTIBODIES AGAINST MHC-BOUND HUMAN DICKKOPF-1 PEPTIDES AND USES THEREOF | July 2021 | January 2025 | Allow | 42 | 1 | 1 | Yes | No |
| 17377922 | Compositions Comprising CD34+ Cells and Methods for Repairing a Lung Injury After Severe Virus Infection | July 2021 | June 2024 | Abandon | 35 | 1 | 0 | No | No |
| 17374227 | NEURODEGENERATIVE DISORDERS | July 2021 | July 2024 | Allow | 36 | 1 | 1 | Yes | No |
| 17418271 | COMPOUNDS AND METHODS FOR TREATMENT OF HEAD AND NECK CANCER | June 2021 | April 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17290960 | NEDD9 IN PULMONARY VASCULAR THROMBOEMBOLIC DISEASE | May 2021 | October 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17212424 | Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody | March 2021 | July 2024 | Allow | 39 | 3 | 0 | Yes | No |
| 17277906 | DUAL ACTING CD1D IMMUNOGLOBULIN | March 2021 | August 2024 | Allow | 41 | 0 | 1 | Yes | No |
| 17277984 | NOVEL BISPECIFIC ANTIBODIES FOR USE IN THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES | March 2021 | April 2024 | Allow | 37 | 0 | 1 | Yes | No |
| 17278259 | AN ANTI-OX40 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF, AND THE PHARMACEUTICAL USE | March 2021 | October 2024 | Allow | 43 | 1 | 1 | Yes | No |
| 17275647 | Improved Anti-FLT3 Antigen Binding Proteins | March 2021 | November 2024 | Allow | 44 | 2 | 1 | Yes | No |
| 17250734 | ANTIBODIES SPECIFIC FOR NTSR1 AND USES THEREOF | February 2021 | June 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17270405 | MONOCLONAL ANTIBODIES AGAINST HUMAN TIM-3 | February 2021 | July 2024 | Allow | 40 | 0 | 1 | Yes | No |
| 17268925 | ANTIBODIES TO HUMAN ZNT8 | February 2021 | April 2024 | Allow | 38 | 0 | 1 | Yes | No |
| 17162585 | ANTI-MICA/B ANTIBODIES THAT BLOCK MICA/B SHEDDING AND METHODS OF USE | January 2021 | March 2024 | Allow | 38 | 1 | 1 | Yes | No |
| 17264507 | ANTI-BTN3A ANTIBODIES AND THEIR USE IN TREATING CANCER OR INFECTIOUS DISORDERS | January 2021 | March 2024 | Allow | 38 | 1 | 0 | No | No |
| 16972298 | MODULATING ANTIBODY DEPENDENT CELLULAR PHAGOCYTOSIS | December 2020 | November 2024 | Abandon | 47 | 2 | 1 | No | No |
| 17054606 | PHARMACEUTICAL COMPOSITION COMPRISING CCN5 AS ACTIVE INGREDIENT, FOR PREVENTING OR TREATING RETINAL DISEASES | November 2020 | March 2025 | Allow | 52 | 3 | 0 | Yes | No |
| 17044493 | KIR3DL3 AS AN HHLA2 RECEPTOR, ANTI-HHLA2 ANTIBODIES, AND USES THEREOF | October 2020 | June 2024 | Allow | 44 | 1 | 1 | Yes | No |
| 16966232 | NERVE CELL CULTURE MATERIAL AND THERAPEUTIC AGENT FOR NERVE DAMAGE | July 2020 | April 2024 | Abandon | 44 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PETRASH, HILARY ANN.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner PETRASH, HILARY ANN works in Art Unit 1644 and has examined 39 patent applications in our dataset. With an allowance rate of 66.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 38 months.
Examiner PETRASH, HILARY ANN's allowance rate of 66.7% places them in the 20% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by PETRASH, HILARY ANN receive 1.10 office actions before reaching final disposition. This places the examiner in the 16% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by PETRASH, HILARY ANN is 38 months. This places the examiner in the 11% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +61.9% benefit to allowance rate for applications examined by PETRASH, HILARY ANN. This interview benefit is in the 98% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 37.5% of applications are subsequently allowed. This success rate is in the 82% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 100.0% of cases where such amendments are filed. This entry rate is in the 99% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants file petitions regarding this examiner's actions, 40.0% are granted (fully or in part). This grant rate is in the 38% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.